$ENGN News

A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?

enGene Therapeutics hit by analyst downgrades as drug data disappoints

Why Is enGene Therapeutics Stock Falling Friday?

Citizens Downgrades enGene Therapeutics to Market Perform

Guggenheim Downgrades enGene Therapeutics to Neutral

Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2

HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6

Piper Sandler Downgrades enGene Therapeutics to Neutral, Lowers Price Target to $4

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

WBB Securities Initiates Coverage On enGene Therapeutics with Buy Rating, Announces Price Target of $21.5

enGene Announces Name Change to enGene Therapeutics Inc.

enGene Holdings To Change Its Corporate Name To enGene Therapeutics Effective April 8

enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference

enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference

enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update

enGene Holdings: Key Catalysts Incoming For 2026

Oppenheimer Maintains Outperform on enGene Holdings, Lowers Price Target to $30

HC Wainwright & Co. Reiterates Buy on enGene Holdings, Maintains $25 Price Target